KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBT (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EBT for 16 consecutive years, with -$27.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 116.01% year-over-year to -$27.2 million, compared with a TTM value of $482.5 million through Dec 2025, down 10.94%, and an annual FY2025 reading of $482.5 million, down 10.94% over the prior year.
  • EBT was -$27.2 million for Q4 2025 at Biomarin Pharmaceutical, down from -$26.3 million in the prior quarter.
  • Across five years, EBT topped out at $297.9 million in Q2 2025 and bottomed at -$66.6 million in Q4 2021.
  • Average EBT over 5 years is $64.4 million, with a median of $38.3 million recorded in 2022.
  • The sharpest move saw EBT soared 2288.5% in 2023, then plummeted 119.58% in 2025.
  • Year by year, EBT stood at -$66.6 million in 2021, then surged by 73.63% to -$17.6 million in 2022, then surged by 210.08% to $19.3 million in 2023, then surged by 777.73% to $169.6 million in 2024, then crashed by 116.01% to -$27.2 million in 2025.
  • Business Quant data shows EBT for BMRN at -$27.2 million in Q4 2025, -$26.3 million in Q3 2025, and $297.9 million in Q2 2025.